Gv-100

Phase 1

Gv-100 is one of 2 therapeutic programs targeting ADPKD (Autosomal Dominant Polycystic Kidney Disease). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ADPKD (autosomal Dominant Polycystic Kidney Disease)Recruiting

ADPKD (autosomal Dominant Polycystic Kidney Disease)Phase 1

Recruiting

Competition

Competitive Landscape

1 competitor in ADPKD (autosomal Dominant Polycystic Kidney Disease)

#DrugCompanyPhaseTrials

JMKX003142

JJemincare

Phase 1

—2

Gv-100

GGilva Therapeutics Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

ADPKD (autosomal Dominant Polycystic Kidney Disease)

NCT07788014

Clinical

Trials by Indication[1]

ADPKD (Autosomal Dominant Polycystic Kidney Disease)1 trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Asceding Doses of GV-100 With Food-Effect and Drug Drug Interaction Evaluations in Healthy Participants

Recruiting·GGilva Therapeutics Inc.·Phase 1·NCT07788014·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gv-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gv-100. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Gilva Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: GGilva Therapeutics Inc.

Gv-100

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

ADPKD (Autosomal Dominant Polycystic Kidney Disease)1 trial

References

Drug Info

Quick Facts

Related News